Quantification of Osilodrostat in Horse Urine Using LC/ESI-HRMS to Establish an Elimination Profile for Doping Control

Overview

Journal Bioanalysis

Specialty Chemistry

Date 2024 Sep 5

PMID 39235065

Authors

Hideaki Ishii

Ryo Shigematsu

Shunsuke Takemoto

Yuhiro Ishikawa

Fumiaki Mizobe

Motoi Nomura

Daisuke Arima

Hirokazu Kunii

Reiko Yuasa

Takashi Yamanaka

Sohei Tanabe

Shun-Ichi Nagata

Masayuki Yamada

Gary Ngai-Wa Leung

Affiliations

Soon will be listed here.

Abstract

The use of osilodrostat, developed as a medication for Cushing's disease but categorized as an anabolic agent, is banned in horses by both the International Federation of Horseracing Authorities and the Fédération Equestre Internationale. For doping control purposes, elimination profiles of hydrolyzed osilodrostat in horse urine were established and the detectability of free forms of osilodrostat and its major metabolite, mono-hydroxylated osilodrostat (M1c), was investigated. Post-administration urine samples obtained from a gelding and three mares were analyzed to establish the elimination profiles of osilodrostat using a validated method involving efficient enzymatic hydrolysis followed by LC/ESI-HRMS analysis. Applying the validated quantification method with an LLOQ of 0.05 ng/ml, hydrolyzed osilodrostat could be quantified in post-administration urine samples from 48 to 72 h post-administration; by contrast, both hydrolyzed osilodrostat and M1c were detected up to 2 weeks. In addition, confirmatory analysis identified the presence of hydrolyzed osilodrostat for up to 72 h post-administration. For doping control purposes, we recommend monitoring both hydrolyzed M1c and osilodrostat because of the greater detectability of M1c and the availability of a reference material of osilodrostat, which is essential for confirmatory analysis.

References

Ishii H, Shibuya M, Kusano K, Sone Y, Kamiya T, Wakuno A . Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric Characterization of its Novel Metabolites in Equines for the Purpose of Doping Control. Curr Drug Metab. 2022; 23(10):850-865. DOI: 10.2174/1389200223666220825093945. View

Kintz P, Gheddar L, Ameline A, Arbouche N, Raul J . Hair testing for doping agents. What is known and what remains to do. Drug Test Anal. 2020; 12(3):316-322. DOI: 10.1002/dta.2766. View

Thevis M, Geyer H, Tretzel L, Schanzer W . Sports drug testing using complementary matrices: Advantages and limitations. J Pharm Biomed Anal. 2016; 130:220-230. DOI: 10.1016/j.jpba.2016.03.055. View

Li L, Vashisht K, Boisclair J, Li W, Lin T, Schmid H . Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. Toxicol Appl Pharmacol. 2015; 286(3):224-33. DOI: 10.1016/j.taap.2015.05.004. View

Viljanto M, Gray B, Scarth J . Presence and detection of endogenous steroids in the horse-A review. Drug Test Anal. 2023; 16(9):1044-1065. DOI: 10.1002/dta.3624. View

Ishii H, Leung G, Yamashita S, Yamada M, Kushiro A, Kasashima Y . Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry. Rapid Commun Mass Spectrom. 2020; 34(23):e8920. DOI: 10.1002/rcm.8920. View

Ishii H, Shibuya M, Kusano K, Sone Y, Kamiya T, Wakuno A . First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis. J Pharm Biomed Anal. 2023; 235:115600. DOI: 10.1016/j.jpba.2023.115600. View

Cloteau C, Dervilly G, Kaabia Z, Bagilet F, Delcourt V, Loup B . From a non-targeted metabolomics approach to a targeted biomarkers strategy to highlight testosterone abuse in equine. Illustration of a methodological transfer between platforms and laboratories. Drug Test Anal. 2022; 14(5):864-878. DOI: 10.1002/dta.3221. View

Loup B, Andre F, Avignon J, Lhuaire M, Delcourt V, Barnabe A . miRNAs detection in equine plasma by quantitative polymerase chain reaction for doping control: Assessment of blood sampling and study of eca-miR-144 as potential erythropoiesis stimulating agent biomarker. Drug Test Anal. 2021; 14(5):953-962. DOI: 10.1002/dta.3047. View

10.

Ishii H, Shibuya M, Kusano K, Sone Y, Kamiya T, Wakuno A . Segmental analysis and long-term monitoring of vadadustat in equine hair for the purpose of doping control. J Anal Toxicol. 2023; 47(7):623-631. DOI: 10.1093/jat/bkad057. View

11.

Duggan S . Osilodrostat: First Approval. Drugs. 2020; 80(5):495-500. DOI: 10.1007/s40265-020-01277-0. View

12.

Balakirouchenane D, Vasseur A, Bonnet-Serrano F, Choi M, Khoudour N, Puszkiel A . LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing's Syndrome. J Pharm Biomed Anal. 2023; 228:115316. DOI: 10.1016/j.jpba.2023.115316. View

13.

Ishii H, Shibuya M, So Y, Wong J, Ho E, Kusano K . Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control. Drug Test Anal. 2021; 14(2):233-251. DOI: 10.1002/dta.3172. View

14.

Chan G, Ho E, Leung D, Wong K, Wan T . Targeted Metabolomics Approach To Detect the Misuse of Steroidal Aromatase Inhibitors in Equine Sports by Biomarker Profiling. Anal Chem. 2015; 88(1):764-72. DOI: 10.1021/acs.analchem.5b03165. View

15.

Kintz P . Hair Analysis in Forensic Toxicology: An Updated Review with a Special Focus on Pitfalls. Curr Pharm Des. 2017; 23(36):5480-5486. DOI: 10.2174/1381612823666170929155628. View

16.

Dirikolu L, Lehner A . A review of current chemistry, pharmacology, and regulation of endogenous anabolic steroids testosterone, boldenone, and nandrolone in horses. J Vet Pharmacol Ther. 2023; 46(4):201-217. DOI: 10.1111/jvp.13397. View

17.

Ishii H, Leung G, Yamashita S, Nagata S, Kushiro A, Sakai S . Identification of potential biomarkers in urine and plasma after consumption of tobacco product in horses. Drug Test Anal. 2022; 14(5):902-914. DOI: 10.1002/dta.3242. View

18.

Dahlgren A, Knych H, Arthur R, Durbin-Johnson B, Finno C . Transcriptomic Markers of Recombinant Human Erythropoietin Micro-Dosing in Thoroughbred Horses. Genes (Basel). 2021; 12(12). PMC: 8702184. DOI: 10.3390/genes12121874. View

19.

Thevis M, Kuuranne T, Geyer H . Annual banned-substance review-Analytical approaches in human sports drug testing 2021/2022. Drug Test Anal. 2022; 15(1):5-26. DOI: 10.1002/dta.3408. View

20.

Cloteau C, Dervilly G, Loup B, Delcourt V, Kaabia Z, Bagilet F . Performance assessment of an equine metabolomics model for screening a range of anabolic agents. Metabolomics. 2023; 19(4):38. DOI: 10.1007/s11306-023-01985-0. View